KOL Identification

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

A leader in research tools and clinical diagnostic development asked DeciBio to evaluate the opportunity for an ultra-sensitive detection platform in methylation analysis

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic

A research tools start-up enlisted DeciBio to support their go-to-market strategy and activities for their novel sequencing technology by conducting pricing voice-of-customer research and evaluating potential pricing strategies

A diagnostics company asked DeciBio to convene an advisory board (ad board) to help it position its relatively new somatic oncology genomic profiling product in an already competitive market

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings